Degarelix

Degarelix  Struktur
214766-78-6
CAS-Nr.
214766-78-6
Englisch Name:
Degarelix
Synonyma:
Degarelix acetate;FirMagon;Dikarek;DEGARELIX;Degarelix-d7;Peptides Acetate;Degarelix impurity;DEGARELIX USP/EP/BP;Degarelix acetate salt;Degarelix, Degarelix acetate
CBNumber:
CB52448443
Summenformel:
C82H103ClN18O16
Molgewicht:
1632.26
MOL-Datei:
214766-78-6.mol

Degarelix Eigenschaften

Dichte
1.325±0.06 g/cm3(Predicted)
storage temp. 
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
Löslichkeit
DMSO:10.0(Max Conc. mg/mL);6.13(Max Conc. mM)
H2O:25.0(Max Conc. mg/mL);15.32(Max Conc. mM)
pka
10.38±0.40(Predicted)
Aggregatzustand
Solid
Farbe
White to off-white
Sequenz
Ac-D-2-Nal-D-4-Cl-Phe-D-3-Pal-Ser-4-Aph(Hor)-4-D-Aph(Cbm)-Leu-Lys(ipr)-Pro-D-Ala-NH2
InChIKey
MEUCPCLKGZSHTA-XYAYPHGZSA-N
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Achtung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H360 Kann die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen. Fertility (Fruchtbarkeit) Kategorie 1 Achtung GHS hazard pictogramssrc="/GHS08.jpg" width="20" height="20" />
Sicherheit

Degarelix Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Antagonists of GnRH have proven to be an effective therapy for hormonally regulated cancers, such as prostate and some types of breast. As analogs of GnRH, they bind competitively and reversibly to GnRH receptors in the pituitary gland, thereby blocking the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In men, the reduction of LH triggers the ablation of testosterone secretion from the testes, and these castration-like levels have been essential in the effective management of advanced prostate cancer. In comparison to GnRH agonists, antagonists do not suffer from a potential flare of the disease as a result of an initial stimulation of the hypothalamic-pituitary-gonadal axis prior to down-regulation of the GnRH receptor. Moreover, GnRH antagonists provide beneficial effects more rapidly postdosing and result in a more efficient suppression of gonadotropin levels. With this in mind, degarelix acetate has been launched as a third-generation GnRH antagonist for the treatment of prostate cancer, and it joins other third-generation agents, ganirelix and cetronelix, on the market.

Verwenden

Degarelix, is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist.

Clinical Use

Ferring launched degarelix acetate, a gonadotrophin-releasing hormone (GnRH) antagonist, in 2009 in the U.S. for the treatment of prostate cancer. The compound has been approved by the E.U. for the same indication, and in the same year it was launched in the UK and Germany. Degarelix has been developed as a one-month or three-month sustained-release injectable formulation. Compared to other GnRH antagonists, degarelix displays improved aqueous solubility, longer acting effects and weaker histamine-releasing properties.

Nebenwirkungen

The most common adverse events included injection site reactions (pain, erythema, swelling, or induration), hot flashes, increased weight, and increases in serum levels of transaminases and gamma-glutamyltransferase. In addition to being contraindicated in patients with a previous hypersensitivity to degarelix, it should not be administered to women who are or may become pregnant as fetal harm can occur. Since long-term androgen deprivation therapy prolongs the QT interval, physicians should consider whether the benefits of degarelix outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure or in patients taking antiarrhythmic medications.

Degarelix Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Degarelix Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 267)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Shandong Huizhihan Supply Chain Co., Ltd
+86-13363081709 +86-13363000288
3957328362@qq.com China 300 58
AFINE CHEMICALS LIMITED
+86-0571-85134551
sales@afinechem.com China 15144 58
Apextide Co Ltd
+8615300650552
info@apextide.com China 92 58
Zibo Hangyu Biotechnology Development Co., Ltd
+86-0533-2185556 +8615965530500
nickzhang@hangyubiotech.com China 10997 58
Chengdu Shengnuo Biopharm Co.,Ltd
+8613953333566
sinobiopharm@gmail.com China 28 58
Henan Bao Enluo International TradeCo.,LTD
+86-17331933971
deasea125996@gmail.com China 2472 58
Anhui Ruihan Technology Co., Ltd
+8617756083858
daisy@anhuiruihan.com China 973 58
Nantong Guangyuan Chemicl Co,Ltd
+undefined17712220823
admin@guyunchem.com China 615 58
Chongqing Soarwin Technology Co., Ltd
+86-15790943001
crystal@sorawin.cn China 421 58
Xi an Biohorlden Industry Trade Co Ltd
+86-18829283179 +86-13636819721
sales@horlden.com China 317 58

214766-78-6()Verwandte Suche:


  • DEGARELIX
  • Degarelix acetate
  • N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-4-[2,6-dioxohexahydropyrimidin-4(S)-ylcarboxamido]-L-phenylalanyl-4-ureido-D-phenylalanyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide acetate
  • Degarelix acetate salt
  • D-Alaninamide, N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-
  • Degarelix acetate(FE-200486,Degarelix)
  • FirMagon
  • Degarelix, Degarelix acetate
  • D-Alaninamide,N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-ly
  • D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-
  • Degarelix impurity
  • DEGARELIX USP/EP/BP
  • Degarelix-d7
  • Dikarek
  • Peptides Acetate
  • D7-Degarelix Trifluoroacetate
  • 214766-78-6
  • 217466-78-6
  • C82H103ClN18O16C2H4O2
  • C82H103N18O16Cl
  • C82H103ClN18O16
  • API
Copyright 2019 © ChemicalBook. All rights reserved